2026 Q2 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Irtoamispäivä 14.8.
3,83%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenNow Sunday evening 😊 What expectations do you have for the coming week for the Novo share?
·15 t sittenwhat is the website in Dannmark if one wants to see updated insider trades?
Hi, Unfortunately, in Denmark there is no public, searchable insider register like in Sweden. Insider trades are typically published via the companies' stock exchange announcements, and the underlying reports go to Finanstilsynet. The most commonly used places are: Nasdaq Copenhagen company announcements https://view.news.eu.nasdaq.com Search for the company (e.g. Novo Nordisk) and filter by Managers' Transactions / ledelsens transaktioner. Finanstilsynet https://www.finanstilsynet.dk Describes the rules and receives the reports, but does not offer a comprehensive public searchable insider register. Third-party services E.g. TradeDesk, which collects Danish insider trades from the stock exchange announcements and gathers them in one place.
·16 t sitten · MuokattuSemaglutide slowed biological aging measured by several epigenetic clocks in a randomized, double-blind, placebo-controlled clinical trial. The clearest signals were seen in epigenetic measurements associated with inflammation as well as brain, heart, blood, kidney, liver, and metabolic health. This suggests that the drug may potentially affect aging-related biology in several different organ systems. - The interesting thing is that Novo already has a concrete signal. If later trials show that semaglutide can actually delay biological aging and thereby reduce age-related diseases, it could potentially significantly expand the market. https://today.ucsd.edu/story/study-popular-glp-1-drug-may-slow-down-biological-aging?fbclid=IwdGRjcATlA4lwZG9mBWZkaWQWUMLEopSKCwA3526MVKocZKwjpVDYHmV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR42GXT2M7Sw_Ck7ueR4vPqwxbD11Ak3RyDJLuUJBWyNht02i2pJY-HVxv1M0w_aem_AwgKAsppdsIUNOfUOSaW6g&utm_id=97757_v0_s00_e0_tv2_a1dennhbazjfyo
It seems that. Semaglutide has the same effect on the body as exercise and healthy diet. I wonder if it also increases the fitness level.
·1 päivä sittenValuation of Eli Lilly versus Novo Nordisk It is quite obvious that it is Eli Lilly's growth that gives the high valuation compared to Novo Nordisk, and that Eli Lilly's growth so far has come at the expense of Novo Nordisk in the injection market. The valuation indicators often used to evaluate growth companies are PEG and PEGY. Explanations of these indicators can be found online. Companies with a PEG or PEGY value below 1 are considered undervalued or underpriced in relation to the expected growth. Eli Lilly has had a value below 1 until now. If one assumes that the rest of the year will be like the second quarter, AI claims that the PEG and PEGY value for Eli Lilly will be 1. This means that the company is neither over- nor underpriced, but has a fair valuation. Novo Nordisk has performed very poorly on these indicators because the company has lost growth to Eli Lilly. Regarding the way forward, it is likely that competition will continue to increase. This could lead to lower growth for Eli Lilly in the injection market, where the company competes with Novo Nordisk. In the tablet market, the situation is different. We have confirmed that this market is larger, partly because many are afraid of needles, and because the treatment has been expensive. The tablet removes the fear of needles, while prices have come down. The launch in the UK is an example of this. In this market, Novo Nordisk can achieve growth without facing equally strong competition from Eli Lilly. Much indicates that Eli Lilly's tablet is the clearly weakest product, and that there are more customers to compete for. The same is evident from the launch of the tablet in the United Arab Emirates, where Novo Nordisk had already achieved a market share of 50 percent, even though Foundayo was already established in the market. This can therefore give Novo Nordisk important growth, which in turn can positively impact the PEG and PEGY indicators and lead to a better valuation of the company. So the conclusion is that if Novo manages to continue to maintain low growth in the injection market while there is strong growth from the pill market, this could provide a significant contribution and repricing of Novo.Good that someone finally addresses p/e to growth = PEG. It's not quite as simple as you present it. According to Yahoo Finance, LLY has a PEG = 1.56 and NVO has a PEG = 3.08. This means that LLY is priced cheaply (<2) and NVO expensively (>2), because the industry's fair PEG value typically lies closer to 2 than 1. Therefore, NVO is traded at a premium, because its PEG implies a future growth of merely 13/3.08 = 4%. The market accounts for this growth being modest, that there is a large upside, which is why a high premium is given (read: PEG > fair price) With LLY, it's the exact opposite. Here, you essentially get a penalty because the growth of 33/1.56 = 22% is less than what LLY itself announces. The market accounts for lower growth, because, unlike NVO, there is a significant downside.
1 päivä sittenTämä julkaisu on poistettu.Retatrutide is a very potent medicine. In relation to obesity, I believe this could become a niche product as there are quite a few more side effects associated with its use. Up to 20 percent stopped using it. It is also unclear how large the fat- vs muscle loss ratio will be. With such a large weight reduction, a significant amount of muscle mass can also be lost. Cagrisema will be introduced in early 2027 as a competitor to zepbound and this has the potential to be better than Zepbound, when one gets to test several different doses between the two different active substances. Now they are considered equally good for obesity, but zepbound is better at lowering blood sugar.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Irtoamispäivä 14.8.
3,83%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenNow Sunday evening 😊 What expectations do you have for the coming week for the Novo share?
- ·15 t sittenwhat is the website in Dannmark if one wants to see updated insider trades?Hi, Unfortunately, in Denmark there is no public, searchable insider register like in Sweden. Insider trades are typically published via the companies' stock exchange announcements, and the underlying reports go to Finanstilsynet. The most commonly used places are: Nasdaq Copenhagen company announcements https://view.news.eu.nasdaq.com Search for the company (e.g. Novo Nordisk) and filter by Managers' Transactions / ledelsens transaktioner. Finanstilsynet https://www.finanstilsynet.dk Describes the rules and receives the reports, but does not offer a comprehensive public searchable insider register. Third-party services E.g. TradeDesk, which collects Danish insider trades from the stock exchange announcements and gathers them in one place.
- ·16 t sitten · MuokattuSemaglutide slowed biological aging measured by several epigenetic clocks in a randomized, double-blind, placebo-controlled clinical trial. The clearest signals were seen in epigenetic measurements associated with inflammation as well as brain, heart, blood, kidney, liver, and metabolic health. This suggests that the drug may potentially affect aging-related biology in several different organ systems. - The interesting thing is that Novo already has a concrete signal. If later trials show that semaglutide can actually delay biological aging and thereby reduce age-related diseases, it could potentially significantly expand the market. https://today.ucsd.edu/story/study-popular-glp-1-drug-may-slow-down-biological-aging?fbclid=IwdGRjcATlA4lwZG9mBWZkaWQWUMLEopSKCwA3526MVKocZKwjpVDYHmV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR42GXT2M7Sw_Ck7ueR4vPqwxbD11Ak3RyDJLuUJBWyNht02i2pJY-HVxv1M0w_aem_AwgKAsppdsIUNOfUOSaW6g&utm_id=97757_v0_s00_e0_tv2_a1dennhbazjfyoIt seems that. Semaglutide has the same effect on the body as exercise and healthy diet. I wonder if it also increases the fitness level.
- ·1 päivä sittenValuation of Eli Lilly versus Novo Nordisk It is quite obvious that it is Eli Lilly's growth that gives the high valuation compared to Novo Nordisk, and that Eli Lilly's growth so far has come at the expense of Novo Nordisk in the injection market. The valuation indicators often used to evaluate growth companies are PEG and PEGY. Explanations of these indicators can be found online. Companies with a PEG or PEGY value below 1 are considered undervalued or underpriced in relation to the expected growth. Eli Lilly has had a value below 1 until now. If one assumes that the rest of the year will be like the second quarter, AI claims that the PEG and PEGY value for Eli Lilly will be 1. This means that the company is neither over- nor underpriced, but has a fair valuation. Novo Nordisk has performed very poorly on these indicators because the company has lost growth to Eli Lilly. Regarding the way forward, it is likely that competition will continue to increase. This could lead to lower growth for Eli Lilly in the injection market, where the company competes with Novo Nordisk. In the tablet market, the situation is different. We have confirmed that this market is larger, partly because many are afraid of needles, and because the treatment has been expensive. The tablet removes the fear of needles, while prices have come down. The launch in the UK is an example of this. In this market, Novo Nordisk can achieve growth without facing equally strong competition from Eli Lilly. Much indicates that Eli Lilly's tablet is the clearly weakest product, and that there are more customers to compete for. The same is evident from the launch of the tablet in the United Arab Emirates, where Novo Nordisk had already achieved a market share of 50 percent, even though Foundayo was already established in the market. This can therefore give Novo Nordisk important growth, which in turn can positively impact the PEG and PEGY indicators and lead to a better valuation of the company. So the conclusion is that if Novo manages to continue to maintain low growth in the injection market while there is strong growth from the pill market, this could provide a significant contribution and repricing of Novo.Good that someone finally addresses p/e to growth = PEG. It's not quite as simple as you present it. According to Yahoo Finance, LLY has a PEG = 1.56 and NVO has a PEG = 3.08. This means that LLY is priced cheaply (<2) and NVO expensively (>2), because the industry's fair PEG value typically lies closer to 2 than 1. Therefore, NVO is traded at a premium, because its PEG implies a future growth of merely 13/3.08 = 4%. The market accounts for this growth being modest, that there is a large upside, which is why a high premium is given (read: PEG > fair price) With LLY, it's the exact opposite. Here, you essentially get a penalty because the growth of 33/1.56 = 22% is less than what LLY itself announces. The market accounts for lower growth, because, unlike NVO, there is a significant downside.
- 1 päivä sittenTämä julkaisu on poistettu.Retatrutide is a very potent medicine. In relation to obesity, I believe this could become a niche product as there are quite a few more side effects associated with its use. Up to 20 percent stopped using it. It is also unclear how large the fat- vs muscle loss ratio will be. With such a large weight reduction, a significant amount of muscle mass can also be lost. Cagrisema will be introduced in early 2027 as a competitor to zepbound and this has the potential to be better than Zepbound, when one gets to test several different doses between the two different active substances. Now they are considered equally good for obesity, but zepbound is better at lowering blood sugar.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
UUTTA
4 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Irtoamispäivä 14.8.
3,83%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenNow Sunday evening 😊 What expectations do you have for the coming week for the Novo share?
- ·15 t sittenwhat is the website in Dannmark if one wants to see updated insider trades?Hi, Unfortunately, in Denmark there is no public, searchable insider register like in Sweden. Insider trades are typically published via the companies' stock exchange announcements, and the underlying reports go to Finanstilsynet. The most commonly used places are: Nasdaq Copenhagen company announcements https://view.news.eu.nasdaq.com Search for the company (e.g. Novo Nordisk) and filter by Managers' Transactions / ledelsens transaktioner. Finanstilsynet https://www.finanstilsynet.dk Describes the rules and receives the reports, but does not offer a comprehensive public searchable insider register. Third-party services E.g. TradeDesk, which collects Danish insider trades from the stock exchange announcements and gathers them in one place.
- ·16 t sitten · MuokattuSemaglutide slowed biological aging measured by several epigenetic clocks in a randomized, double-blind, placebo-controlled clinical trial. The clearest signals were seen in epigenetic measurements associated with inflammation as well as brain, heart, blood, kidney, liver, and metabolic health. This suggests that the drug may potentially affect aging-related biology in several different organ systems. - The interesting thing is that Novo already has a concrete signal. If later trials show that semaglutide can actually delay biological aging and thereby reduce age-related diseases, it could potentially significantly expand the market. https://today.ucsd.edu/story/study-popular-glp-1-drug-may-slow-down-biological-aging?fbclid=IwdGRjcATlA4lwZG9mBWZkaWQWUMLEopSKCwA3526MVKocZKwjpVDYHmV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR42GXT2M7Sw_Ck7ueR4vPqwxbD11Ak3RyDJLuUJBWyNht02i2pJY-HVxv1M0w_aem_AwgKAsppdsIUNOfUOSaW6g&utm_id=97757_v0_s00_e0_tv2_a1dennhbazjfyoIt seems that. Semaglutide has the same effect on the body as exercise and healthy diet. I wonder if it also increases the fitness level.
- ·1 päivä sittenValuation of Eli Lilly versus Novo Nordisk It is quite obvious that it is Eli Lilly's growth that gives the high valuation compared to Novo Nordisk, and that Eli Lilly's growth so far has come at the expense of Novo Nordisk in the injection market. The valuation indicators often used to evaluate growth companies are PEG and PEGY. Explanations of these indicators can be found online. Companies with a PEG or PEGY value below 1 are considered undervalued or underpriced in relation to the expected growth. Eli Lilly has had a value below 1 until now. If one assumes that the rest of the year will be like the second quarter, AI claims that the PEG and PEGY value for Eli Lilly will be 1. This means that the company is neither over- nor underpriced, but has a fair valuation. Novo Nordisk has performed very poorly on these indicators because the company has lost growth to Eli Lilly. Regarding the way forward, it is likely that competition will continue to increase. This could lead to lower growth for Eli Lilly in the injection market, where the company competes with Novo Nordisk. In the tablet market, the situation is different. We have confirmed that this market is larger, partly because many are afraid of needles, and because the treatment has been expensive. The tablet removes the fear of needles, while prices have come down. The launch in the UK is an example of this. In this market, Novo Nordisk can achieve growth without facing equally strong competition from Eli Lilly. Much indicates that Eli Lilly's tablet is the clearly weakest product, and that there are more customers to compete for. The same is evident from the launch of the tablet in the United Arab Emirates, where Novo Nordisk had already achieved a market share of 50 percent, even though Foundayo was already established in the market. This can therefore give Novo Nordisk important growth, which in turn can positively impact the PEG and PEGY indicators and lead to a better valuation of the company. So the conclusion is that if Novo manages to continue to maintain low growth in the injection market while there is strong growth from the pill market, this could provide a significant contribution and repricing of Novo.Good that someone finally addresses p/e to growth = PEG. It's not quite as simple as you present it. According to Yahoo Finance, LLY has a PEG = 1.56 and NVO has a PEG = 3.08. This means that LLY is priced cheaply (<2) and NVO expensively (>2), because the industry's fair PEG value typically lies closer to 2 than 1. Therefore, NVO is traded at a premium, because its PEG implies a future growth of merely 13/3.08 = 4%. The market accounts for this growth being modest, that there is a large upside, which is why a high premium is given (read: PEG > fair price) With LLY, it's the exact opposite. Here, you essentially get a penalty because the growth of 33/1.56 = 22% is less than what LLY itself announces. The market accounts for lower growth, because, unlike NVO, there is a significant downside.
- 1 päivä sittenTämä julkaisu on poistettu.Retatrutide is a very potent medicine. In relation to obesity, I believe this could become a niche product as there are quite a few more side effects associated with its use. Up to 20 percent stopped using it. It is also unclear how large the fat- vs muscle loss ratio will be. With such a large weight reduction, a significant amount of muscle mass can also be lost. Cagrisema will be introduced in early 2027 as a competitor to zepbound and this has the potential to be better than Zepbound, when one gets to test several different doses between the two different active substances. Now they are considered equally good for obesity, but zepbound is better at lowering blood sugar.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt